文献速递牙体牙髓病

不同麻醉药对不可逆性牙髓炎下牙槽神经阻滞疗效的网络系统综述与meta分析

Different anesthetics on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis: A network systematic review and meta-analysis.
PubMed 文献 · J Am Dent Assoc · 2019-12-06

该系统综述与网状meta分析检索多个数据库,纳入16项比较不同麻醉药在不可逆性牙髓炎患者下牙槽神经阻滞(IANB)中疗效的随机临床试验。混合治疗比较显示阿替卡因与利多卡因差异显著,阿替卡因成功率更高(RR 0.76,95%CI 0.63-0.88),证据质量高;各药成功概率排序为阿替卡因73%、丙胺卡因57%、甲哌卡因55%、布比卡因53%、利多卡因12%。结论认为阿替卡因可提高IANB成功率,利多卡因效果最差。

要点

  • 阿替卡因用于不可逆性牙髓炎患者IANB的成功率高于利多卡因(RR 0.76,95%CI 0.63-0.88)。
  • 各麻醉药IANB成功概率:阿替卡因73%、丙胺卡因57%、甲哌卡因55%、布比卡因53%、利多卡因12%。
  • 利多卡因在纳入的麻醉药中IANB效果最差,临床可优先考虑阿替卡因。

核心结论

  • 使用阿替卡因可提高不可逆性牙髓炎患者下牙槽神经阻滞的成功率。
  • 在比较的麻醉药中,利多卡因的下牙槽神经阻滞效果最差。

研究设计与样本

  • 检索MEDLINE相关数据库(PubMed、Scopus、Web of Science、Cochrane Central Register of Controlled Trials、LILACS、Brazilian Library of Dentistry),不限发表年份和语种,并探索灰色文献。
  • 仅纳入比较不同麻醉药在不可逆性牙髓炎患者IANB疗效的随机临床试验,采用Cochrane协作网工具评估偏倚风险。
  • 共识别7,981项研究,最终16项符合纳入标准并全部进行meta分析。
  • 采用随机效应贝叶斯混合治疗比较模型比较不同麻醉溶液,纳入低或不明确偏倚风险的随机临床试验。
  • 使用Cochran Q检验和I2统计量评估异质性,采用GRADE方法评估证据质量。

主要发现

  • 在混合治疗比较分析中,利多卡因与阿替卡因比较差异显著,阿替卡因成功率更高(风险比0.76,95%CI 0.63-0.88),该比较证据质量高。
  • 各治疗成功概率为:阿替卡因73%、丙胺卡因57%、甲哌卡因55%、布比卡因53%、利多卡因12%,该排序证据质量高。

关键数值与推荐

  • 阿替卡因对比利多卡因的IANB成功风险比0.76(95%CI 0.63-0.88),证据质量高。
  • IANB成功概率:阿替卡因73%、丙胺卡因57%、甲哌卡因55%、布比卡因53%、利多卡因12%,排序证据质量高。

临床怎么用

  • 对不可逆性牙髓炎患者行下牙槽神经阻滞时,可优先选用阿替卡因以提高成功率。
  • 利多卡因在不可逆性牙髓炎患者IANB中效果最差,临床选择麻醉药时需考虑此证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The authors of this systematic review and meta-analysis aimed to evaluate the effect of different anesthetics on the efficacy of inferior alveolar nerve block (IANB) in patients with irreversible pulpitis. TYPES OF STUDIES REVIEWED: The authors conducted a search of MEDLINE databases (PubMed, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, Latin American and Caribbean Health Sciences Literature, and Brazilian Library of Dentistry). There was no restriction on publication year or idiom. The gray literature was also explored. The authors included only randomized clinical trials that compared different anesthetics in the efficacy of IANB in patients with irreversible pulpitis. The risk of bias was evaluated by using the Cochrane Collaboration's tool. A random-effects Bayesian mixed treatment comparison model was used to compare different anesthetic solutions in randomized clinical trials with low or unclear risk of bias. Heterogeneity was assessed by using Cochran Q test and I2 statistics. Quality of evidence was assessed by using the Grading of Recommendations Assessment, Development and Evaluation approach. RESULTS: A total of 7,981 studies were identified; only 16 met the eligibility criteria, and they were all meta-analyzed. A significant difference was observed in the pair lidocaine versus articaine, with higher success with articaine (risk ratio, 0.76; 95% confidence interval, 0.63 to 0.88) in the mixed treatment comparison analysis, as this comparison was graded as high-quality evidence. The probability of success for each treatment was 73% for articaine, 57% for prilocaine, 55% for mepivacaine, 53% for bupivacaine, and 12% for lidocaine. This ranking was considered high quality of evidence. CONCLUSIONS AND PRACTICAL IMPLICATIONS: The use of articaine can increase the IANB success rate in patients with irreversible pulpitis. Among the anesthetic solutions, lidocaine was the least effective.

来源:J Am Dent Assoc,查看原文。版权归原作者所有。

引用

  1. Larocca de Geus J, Nogueira da Costa JK, Wambier LM, et al. Different anesthetics on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis: A network systematic review and meta-analysis. J Am Dent Assoc. 2019. PMID: 31813471. doi:10.1016/j.adaj.2019.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。